FORT LEE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Alpharma Inc. announced that the company will release its third quarter 2005 earnings after the market close on Monday, November 7, 2005. Alpharma management will conduct a conference call/webcast on Tuesday, November 8, 2005 beginning at 8:30 AM Eastern Standard Time to discuss its third quarter results.
The call will be open to all interested parties and may be accessed by using the following information:
CONFERENCE CALL ACCESS Domestic Dial In: (800) 374-0147 International Dial In: (706) 634-5431 Conference Call ID: 1924965
Investors can access the call in a “listen only” mode via the Internet at http://www.streetevents.com or http://www.companyboardroom.com.
In addition, for those unable to participate at the time of the call, a rebroadcast will be available following the call from Tuesday, November 8, 2005 at 12:00 PM Eastern Standard Time until Tuesday, November 15, 2005 at midnight. The rebroadcast may be accessed on the Internet at http://www.streetevents.com or by telephone using the following information:
REBROADCAST ACCESS Domestic Dial In: (800) 642-1687 International Dial In: (706) 645-9291 Participant Code: 1924965
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma is a leading manufacturer of generic pharmaceutical products in the U.S., and also has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. It is also one of the largest suppliers of generic solid dose pharmaceuticals in Europe, with a growing presence in Southeast Asia. The company is a worldwide producer of key active pharmaceutical ingredients. Alpharma is among the world’s leading producers of several important pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Alpharma Inc.
CONTACT: Kathleen Makrakis, VP, Investor Relations, of Alpharma Inc.,+1-201-228-5085, kathleen.makrakis@alpharma.com
